Last updated: October 25, 2026
UZEDY is Teva Pharmaceuticals’ long-acting injectable risperidone for schizophrenia in adults. FDA approval in April 2023 gave Teva a differentiated product in a large long-acting injectable antipsychotic market. Its monthly and twice-monthly dosing, subcutaneous administration, and lack of a required oral supplementation period support adoption, but UZEDY competes against entrenched products from Johnson & Johnson, Otsuka, Alkermes, and Luye Pharma.
Teva’s reported UZEDY sales increased from an early-stage launch base in 2023 to an annualized trajectory in the low hundreds of millions of dollars by 2024. The commercial case depends on converting patients from oral risperidone and older long-acting injectables, expanding use among Medicaid and community mental-health patients, and maintaining reimbursement access.
What is UZEDY and how does it work?
UZEDY is a subcutaneous extended-release injectable suspension containing risperidone. Teva developed the product with MedinCell using MedinCell’s BEPO technology, an extended-release delivery platform based on biodegradable polymers.
FDA-approved dosing includes:
| Product attribute |
UZEDY profile |
| Active ingredient |
Risperidone |
| Therapeutic category |
Long-acting atypical antipsychotic |
| Indication |
Treatment of schizophrenia in adults |
| Administration |
Subcutaneous injection by a healthcare professional |
| Dosing intervals |
Once monthly or once every two months |
| Monthly strengths |
50 mg, 75 mg, 100 mg, 125 mg |
| Twice-monthly strengths |
100 mg, 125 mg, 150 mg, 200 mg, 250 mg |
| Oral supplementation |
Not required under the FDA label |
| Initial approval |
April 28, 2023 |
| Sponsor |
Teva Pharmaceuticals USA |
UZEDY can be initiated the day after the last dose of oral risperidone at an appropriate dose. The absence of a required oral overlap period simplifies initiation compared with some older long-acting injectable regimens. FDA labeling also describes administration using a prefilled syringe and a short subcutaneous injection procedure (U.S. Food and Drug Administration, 2023).
How large is the market for long-acting injectable antipsychotics?
The U.S. long-acting injectable antipsychotic market is concentrated in branded products and has expanded as providers place greater emphasis on adherence, relapse prevention, and reduced hospitalization risk.
The principal products competing with UZEDY are:
| Product |
Company |
Active ingredient |
Typical interval |
Competitive position |
| Invega Sustenna |
Johnson & Johnson |
Paliperidone palmitate |
Monthly |
Market-leading LAI franchise |
| Invega Trinza |
Johnson & Johnson |
Paliperidone palmitate |
Every three months |
Longer-interval paliperidone product |
| Invega Hafyera |
Johnson & Johnson |
Paliperidone palmitate |
Every six months |
Longest-duration major LAI |
| Abilify Maintena |
Otsuka/Lundbeck |
Aripiprazole |
Monthly |
Established aripiprazole franchise |
| Abilify Asimtufii |
Otsuka/Lundbeck |
Aripiprazole |
Every two months |
Longer-duration aripiprazole option |
| Aristada |
Alkermes |
Aripiprazole lauroxil |
Monthly to every six months |
Flexible dosing and Initio initiation option |
| Perseris |
Indivior |
Risperidone |
Monthly |
Subcutaneous risperidone competitor |
| UZEDY |
Teva/MedinCell |
Risperidone |
Monthly or every two months |
Subcutaneous risperidone with no oral overlap |
The commercial opportunity is narrower than the total schizophrenia drug market because UZEDY addresses patients selected for injectable treatment. Its more realistic market is the U.S. LAI segment, particularly risperidone users and patients for whom providers prefer a shorter needle, subcutaneous administration, or a two-month regimen.
What drove UZEDY’s early commercial uptake?
UZEDY’s initial uptake has been supported by four factors.
First, UZEDY addresses a familiar molecule. Risperidone has a long clinical history, and prescribers do not need to adopt a new pharmacologic mechanism.
Second, the product has two administration intervals. Monthly dosing creates a direct alternative to Perseris and monthly risperidone regimens. The two-month formulation gives Teva a way to compete with longer-interval products.
Third, UZEDY does not require oral supplementation after initiation under the FDA label. That reduces operational complexity for clinics and may improve initiation in outpatient settings.
Fourth, Teva has an established specialty and institutional sales infrastructure. The company can promote UZEDY through existing relationships with psychiatrists, community mental-health centers, hospitals, and specialty pharmacies.
The main adoption barriers are payer restrictions, provider familiarity with competing LAIs, prior authorization requirements, injection-site considerations, and the need for repeated healthcare encounters. UZEDY is administered by a healthcare professional, so its commercial model depends on office-based and clinic-based reimbursement.
What is UZEDY’s sales trajectory?
Teva reported UZEDY as a growth product within its innovative-medicines portfolio. Public disclosures show a rapid sequential increase after the April 2023 launch.
| Period |
UZEDY commercial status |
| April 2023 |
FDA approval and U.S. launch |
| 2023 |
Initial formulary placement, provider education, and early patient conversion |
| 2024 |
Broader payer and provider penetration with rising quarterly sales |
| 2025 onward |
Expansion depends on share gains against established LAIs and reimbursement execution |
Teva has identified UZEDY as one of its newer growth drivers and has described the product as having peak-sales potential of more than $1 billion in prior investor communications. That target is a management projection rather than a guaranteed outcome. Reaching it would require UZEDY to become a material share product in the U.S. LAI market, achieve sustained reimbursement coverage, and expand beyond early adopters.
The financial trajectory has a characteristic launch profile:
- Low initial revenue during formulary and prescribing ramp-up.
- Rapid percentage growth from a small base.
- Increasing contribution from repeat injections and dose conversions.
- Slower growth as the product encounters entrenched competitors and payer controls.
- Longer-term operating leverage if sales infrastructure is already in place.
UZEDY’s economics also include obligations to MedinCell under the collaboration. Teva records product revenue, while MedinCell receives milestone payments and royalties linked to commercial performance under the parties’ agreement (MedinCell, 2018; Teva Pharmaceutical Industries Ltd., 2024).
How does UZEDY compare with Perseris?
UZEDY is the closest direct commercial comparator because both products are subcutaneous long-acting risperidone injections.
| Factor |
UZEDY |
Perseris |
| Sponsor |
Teva |
Indivior |
| Molecule |
Risperidone |
Risperidone |
| Administration |
Subcutaneous |
Subcutaneous |
| Dosing |
Monthly or every two months |
Monthly |
| Oral overlap |
Not required under UZEDY labeling |
Not required under Perseris labeling |
| Commercial launch |
2023 |
2018 |
| Strategic advantage |
Broader interval choice and Teva distribution |
Earlier market presence |
| Main risk |
New entrant in a crowded LAI market |
Limited dosing flexibility |
UZEDY’s two-month option is a direct differentiation point. Perseris has an earlier launch and established clinical use, but it does not offer the same dosing interval range.
How does UZEDY compare with Invega and Abilify long-acting injectables?
UZEDY competes against larger franchises with greater prescribing history and longer-duration options.
Johnson & Johnson’s Invega portfolio has the strongest interval ladder, ranging from monthly to six-month dosing. Otsuka and Lundbeck’s Abilify franchise has a large installed base and includes the two-month Abilify Asimtufii product. Alkermes competes with flexible Aristada dosing, including six-month administration under specific conditions.
UZEDY’s strongest positioning is not maximum duration. Its differentiation is the combination of risperidone familiarity, subcutaneous delivery, two dosing intervals, and no required oral supplementation. Its weakness is that it entered after competitors had built substantial provider and payer familiarity.
What FDA regulatory protections apply to UZEDY?
UZEDY received FDA approval under the 505(b)(2) pathway. The active ingredient, risperidone, is not new. Regulatory protection therefore centers on the specific extended-release formulation, delivery system, dosage forms, and approved clinical use rather than on composition-of-matter protection for risperidone itself.
FDA regulatory protection includes:
- New Drug Application approval for UZEDY’s formulation and delivery system.
- Any applicable statutory exclusivity associated with the approval.
- Orange Book-listed patents covering formulation, dosage form, administration, or related methods.
- Regulatory barriers applicable to abbreviated applications that rely on UZEDY’s FDA findings.
The product is a small-molecule drug, not a biologic. Biosimilar approval rules do not apply. A competing product would generally pursue an ANDA or 505(b)(2) strategy, depending on how closely it matches UZEDY’s formulation, delivery system, clinical reliance, and labeling.
What patents protect UZEDY?
UZEDY’s patent position is expected to depend primarily on formulation and drug-delivery claims. Risperidone’s original compound patents are expired or commercially irrelevant to UZEDY’s current exclusivity position.
The relevant protection categories are:
Extended-release formulation patents
These patents may cover polymer composition, particle characteristics, drug loading, release kinetics, suspension properties, and stability.
Subcutaneous delivery patents
Claims may cover administration of risperidone through a specific subcutaneous depot, injection volume, needle configuration, or delivery profile.
Dosing and method-of-use patents
Claims may address monthly and two-month dosing, initiation without oral supplementation, treatment conversion, or use in specific patient populations.
Platform and manufacturing rights
MedinCell’s BEPO platform and related manufacturing processes can create barriers even where a competitor avoids literal infringement of a product claim. The practical barrier may involve polymer manufacture, particle engineering, aseptic filling, suspension stability, and reproducible release performance.
UZEDY’s patent strength is therefore likely strongest at the product and process level, not at the molecule level. The commercial value of the estate depends on the breadth of issued claims, patent-term adjustment, terminal disclaimers, Orange Book listings, and the ability to demonstrate infringement through product testing.
When does UZEDY lose exclusivity?
The relevant loss-of-exclusivity date cannot be reduced to one date because UZEDY has several layers of protection.
| Protection layer |
Expected role |
| Risperidone molecule |
Expired or no longer commercially protective |
| FDA approval exclusivity |
Limited statutory period tied to the 505(b)(2) approval |
| Formulation patents |
Primary product protection |
| Delivery-system patents |
Protection for the subcutaneous depot and administration |
| Method-of-use patents |
Potentially narrower protection for dosing or treatment methods |
| Manufacturing know-how |
May remain valuable after patent expiry but is harder to enforce as an exclusivity right |
Generic entry risk is therefore governed by the latest enforceable formulation or delivery patent, subject to patent challenges, claim scope, and litigation outcomes. A public Orange Book review should be conducted against the current FDA listing before relying on a specific expiry date for valuation or transaction analysis (U.S. Food and Drug Administration, n.d.).
Are there Paragraph IV challenges to UZEDY?
No major publicly reported Paragraph IV litigation against UZEDY was identified in the cited public-company and FDA materials through the early commercial period.
A Paragraph IV challenge would require an ANDA applicant to certify that a listed patent is invalid, unenforceable, or not infringed. For a complex long-acting injectable, the technical burden is higher than for a conventional oral tablet because the applicant must address formulation equivalence, release characteristics, suspension behavior, injection performance, and potentially device-related attributes.
The absence of a public challenge does not eliminate future risk. An ANDA applicant may wait until the product has sufficient commercial value or may pursue a 505(b)(2) strategy that creates a different patent and regulatory profile.
What generic entry risks exist for UZEDY?
UZEDY faces five principal entry risks:
- A generic or follow-on injectable may challenge formulation patents.
- A 505(b)(2) applicant may develop a different long-acting risperidone formulation.
- A competitor may avoid UZEDY patents through a different polymer or release mechanism.
- Perseris and other branded products may reduce UZEDY’s share before patent expiry.
- Payers may favor lower-cost risperidone alternatives if clinical differentiation is limited.
Complex injectable products generally have higher development and manufacturing barriers than oral generics. Those barriers can delay entry, but they do not provide the same protection as a broad composition-of-matter patent.
What licensing deals support UZEDY?
UZEDY was developed through a Teva-MedinCell collaboration. Teva obtained rights to develop and commercialize products using MedinCell’s long-acting delivery technology for selected indications and territories. MedinCell supplies the platform technology and receives contractual economic participation through milestones and royalties.
The agreement is strategically important because it gives Teva access to a differentiated delivery platform without internally developing every component of the formulation technology. For MedinCell, UZEDY is a commercial validation asset and a royalty-generating product. For Teva, the arrangement creates variable economics that reduce the need for full internal platform investment but also share product value with the technology partner.
What is the revenue exposure for Teva?
UZEDY is strategically important but remains a small product relative to Teva’s largest franchises, including Austedo, Copaxone, Ajovy, and generic medicines. Its value is tied to growth rather than current absolute revenue.
The principal financial drivers are:
- Net price after rebates and discounts.
- Number of active treated patients.
- Monthly versus two-month dosing mix.
- Persistence and repeat injection rates.
- Medicaid and commercial payer coverage.
- Administration reimbursement for providers.
- Promotional spending.
- Royalty and milestone obligations to MedinCell.
- Manufacturing scale and supply reliability.
The two-month product can improve patient convenience and retention, but it may also reduce the number of annual injections per patient. Teva must therefore balance higher convenience and potential persistence against lower administration frequency.
What is the competitive outlook for UZEDY?
UZEDY has a credible position in the U.S. LAI market, but its growth is unlikely to be automatic. The product must compete against established franchises with longer clinical histories, broader payer relationships, and increasingly extended dosing intervals.
The most likely commercial path is share capture from:
- Oral risperidone patients who are appropriate for injectable therapy.
- Patients using monthly risperidone products.
- Patients for whom providers want a subcutaneous alternative.
- Patients who benefit from a two-month regimen but do not require a six-month product.
- Clinics seeking initiation without oral supplementation.
The main ceiling is competitive intensity. Invega Hafyera and other extended-interval products can reduce switching opportunities by offering fewer annual injections. UZEDY’s commercial advantage is greatest where providers value risperidone familiarity and flexible monthly or two-month dosing over maximum duration.
Key Takeaways
- UZEDY is a Teva long-acting injectable risperidone approved by FDA in April 2023.
- Its principal differentiators are subcutaneous administration, monthly or twice-monthly dosing, and no required oral supplementation under the label.
- The addressable market is the U.S. long-acting injectable antipsychotic segment, not the entire schizophrenia market.
- Teva has identified UZEDY as a growth product with potential peak sales above $1 billion, although that target requires substantial share gains.
- The closest direct competitor is Perseris, while Invega, Abilify Maintena, Abilify Asimtufii, and Aristada create broader competitive pressure.
- Patent value is concentrated in the formulation, delivery system, dosing regimen, and manufacturing technology rather than in risperidone itself.
- UZEDY is a small-molecule product and does not face biosimilar competition.
- Generic entry will likely depend on complex injectable equivalence, formulation patents, delivery claims, and potential 505(b)(2) competition.
- Teva’s collaboration with MedinCell provides access to the BEPO delivery platform but requires royalty and milestone sharing.
- The product’s financial trajectory depends on payer access, clinic adoption, repeat-injection persistence, and conversion from established LAI therapies.
Frequently Asked Questions
Is UZEDY a biologic or a generic drug?
UZEDY is a small-molecule risperidone product. It is neither a biologic nor a generic. It was approved as a branded 505(b)(2) product.
Does UZEDY require oral risperidone overlap?
No. The FDA label permits initiation after the last oral risperidone dose without required oral supplementation, subject to appropriate dose selection.
How often is UZEDY administered?
UZEDY is available as a monthly injection or an injection administered once every two months.
Who manufactures UZEDY?
Teva commercializes UZEDY. The product was developed with MedinCell, whose BEPO technology supports the extended-release delivery system.
Can a generic company copy UZEDY before its patents expire?
A competitor could pursue an ANDA or 505(b)(2) application, but a complex long-acting injectable must address formulation, release, injection, and regulatory-equivalence requirements. Patent and regulatory barriers remain central to launch timing.
References
-
MedinCell. (2018). MedinCell and Teva enter into a global license agreement for long-acting injectable risperidone. MedinCell.
-
Teva Pharmaceutical Industries Ltd. (2024). Annual report on Form 20-F for the year ended December 31, 2023. Teva Pharmaceutical Industries Ltd.
-
U.S. Food and Drug Administration. (2023). UZEDY prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.
